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In prostate cancer cells, TGFf3 inhibits proliferation in earlier stages of the
disease; however the cancer cells become refractory to growth inhibitory effects in
advanced stages where TGFj3 promotes cancer progression and metastasis. Inhibitor of
Differentiation (Id) family of closely related proteins (Id 1- 1d4) are dominant negative
regulators and bHLH transcription factors and in general promote proliferation, and
inhibit differentiation. In the present study, we have investigated the role of Idi and 1d3
proteins in the growth inhibitory effects of TGF~ on prostate cancer cells. The effect of
TGF f3 on proliferation and Idl and Id3 expression were investigated in PZ-HPV7,
DU145, and PC3 cells. Idi silencing through siRNA was also used in DU145 and PC3
cells to examine its role in anti-proliferative and migratory effects of TGFf3. TGFj3
increased expression of Idi and 1d3 in all cell lines followed by a later down regulation of
Idi in PZ-HPV7 expression and DU145 cells but not in PC3 cells. 1d3 expression
remained elevated in all three cell lines. This loss of Idi protein correlated with an
increase of CDKNI p21. Idi knockdown in both DU145 and PC3 cells resulted in
decreased proliferation. However, while TGFf3 caused a further decrease in proliferation
of DU145, but had no further effects in PC3 cells. Knockdown of Idl or 1d3 inhibited
TGFj3linduced migration in PC3 cells. These findings suggest an essential role of Idi
and 1d3 in TGFf3 1 effects on proliferation and migration in prostate cancer cells.
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Transforming growth factor 13 (TGF13), a member of the TGF13 superfamily, plays
a role in embryonic development, wound healing, angiogenesis, proliferation,
differentiation and apoptosis’. Deregulation of TGFI3 signaling has been implicated in
the pathogenesis of a variety of diseases including cancer2. In normal epithelial cells,
TGF13 causes a G, cell cycle arrest, inhibits proliferation, and promotes differentiation or
apoptosis. Paradoxically, in cancer cells, the tumor becomes resistant to TGF13 dependent
growth inhibition and continues to proliferate in the presence of TGFI33’ ~. Moreover, in
advanced stages of cancers, TGF13 1 acts as a tumor promoter by enhancing angiogenesis,
migration and metastasis ~. The underlying molecular mechanisms and intracellular
effectors surrounding these differential effects of TGF13 1 during different stages of cancer
progression are not well understood.
TGFf3 signals through serine/threonine kinase, type I and type II receptors 6
Once activated, this dimeric complex phosphorylates receptor associated Smads (R
Smads) 2 and 3. The Co-Smad, Smad 4, serves as a common partner for R-Smads. Once
phosphorylated, this Smad complex is translocated into the nucleus to regulate target
genes ~. Among the TGF13 target genes are several transcription factors which include
Runt- related transcription factor 1 (RUNX 1), forkhead transcription factors (FOXO),
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specificity protein 1 (Spi), activator protein 1 (AP-1), and basic helix loop helix
transcription factors (bHLH)79. These transcription factors may, therefore, play a role in
TGFf3 dependent effects on target cells.
Basic- helix- loop- helix (bHLH) transcription factors contain a highly conserved
DNA binding basic domain and a helix loop helix domain. Upon hetero- or homo
dimerization, the bHLH proteins bind to DNA and regulate transcription of many genes
involved in cell cycle control and differentiation ~o. Inhibitor of DNA binding, also
known as inhibitor of differentiation (Id) proteins, heterodimerize with basic-helix-loop-
helix (bHLH) transcription factors in order to inhibit DNA binding of bHLH proteins”.
Id proteins contain the HLH- dimerization domain, but lack the basic DNA binding
domain; hence they essentially act as natural dominant negative inhibitors of bHLH
transcriptrion factors, inhibiting their effects on a wide variety of cellular functions’1.
There are four known isoforms (Idi, 1d2, 1d3, 1d4) of Id proteins. Idi, 1d2, and
1d3 are expressed highly in prostate cancers while 1d4 expression is inversely related to
the development of prostate cancer12’ 13• Id 1 expression has been shown to correlate with
enhanced malignant potential of breast, prostate and ovarian tumors13’ 14 Idi acts as a
mediator of tumor cell migration in non-small- cell lung cancers (NSCLC5), thyroid,
bladder, esophageal, and pancreatic cancers’~’9. In mouse development, it was shown
that during early gestation through birth, Idi and Id3 exhibited overlapping expression
patterns, suggesting that these isoforms have similar functions20. In prostate cancer, it
was shown that Id 1 and Id3 exert positive effects on cell proliferation through inhibition
of expression of p16, p21, and p27 inhibitors of cyclin dependent 21 Our
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previous studies have also indicated that Idi and 1d3 silencing by siRNA resulted in loss
of proliferation in prostate cancer cells 12 Although most studies tend to focus on Idi, a
recent study indicated that 1d3 protein was highly expressed in prostate cancer tissue
samples, which correlated with an increased Gleason score22. While Idi- 1d3 isoforms
have been proposed as tumor promoters, 1d4 isoform appears to exert opposing effects on
cancer cells, acting as a tumor suppressor by increasing apoptosis and decreasing
proliferation when expressed in prostate cancer cells23.
Previous studies have shown that TGFf3 1 acts as an upstream effector of Id 1
expression in normal prostate epithelial cells 24 Loss of Idi induced by TGFI31 has also
been shown to be mediated by Smad 3 signaling in breast and colorectal cancer cell lines;
Smad 3 and Smad 4 were shown to bind directly to the Idi promoter 25 In human
prostate epithelial cells, NPTX, Idi promoted TGFJ3 induced cell motility and adhesion.
This effect was mediated through MEK-ERK signaling pathway26. While TGFf3 effects
on Id 1 expression and its role in cell proliferation has been investigated in normal
prostate cells, very little is known about the role of Ids in TGF~3 signaling during its
transition from tumor suppressor to tumor promoter.
Since TGFf3 displays differential effects during tumor progression, the purpose of
this project will be to explore whether these differential effects of TGF~ during different
stages of cancer involve different Id proteins. Idi and 1d3 will be the primary focus since
these two isoforms have been implicated in cell proliferation and metastasis and have
been shown to be involved in TGFf3 effects in other cell types. The overall hypothesis to
be tested in these studies is that TGFf3 regulate the expression of Id proteins which in turn
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mediate its effects on cell proliferation and! or invasive behavior in prostate cancer cells.
To test this hypothesis, the following aims were investigated:
1. To determine the regulation of Idi and 1d3 expression in response to TGFj3 in
prostate cancer cells.
2. To determine the effects of siRNA against Idi or 1d3 on TGFf3 mediated effects
on proliferation and cell motility
3. To determine the intracellular signaling pathways which are involved in
differential effects of TGFI3 on expression of Idi and 1d3 in prostate cancer cell
CHAPTER TWO
REVIEW OF LITERATURE
2.1 Prostate Development and Disease
The prostate is a male exocrine gland found in the mammalian reproductive system of
mammals. A normal human male prostate is about the size of a walnut and sits above the
base of the penis, below the urinary bladder and onto the front wall of the rectum (see
appendix Figure 1) 27
In order to work properly, the prostate needs testosterone, an endogenous androgen, that
is produced by the testicles. Endogenous androgens, such as testosterone, are responsible for
normal growth and development of the male sex organs and for maintenance of secondary
sex characteristics. These effects include growth and maturation of the prostate, seminal
vesicles, penis, and scrotum; development of male hair distribution, such as beard, pubic,
chest, and axillary hair; laryngeal enlargement, vocal cord thickening, and alterations in body
musculature and fat distribution 28
During normal aging, the prostate gland usually grows larger. This hormone-related
enlargement with aging is called benign prostatic hyperplasia (BPH), but this condition is not
associated with prostate cancer. Benign prostatic hyperplasia (BPH), a noncancerous
enlargement of the prostate gland, makes urination difficult and uncomfortable. As the
prostate gland expands, it squeezes the urethra or causes the muscles around the urethra to
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contract, making it difficult to urinate 29 BPH is not cancer, and it does not put you at
increased risk for developing prostate cancer.
Prostate cancer is the second leading cause of cancer death in American men. According
to the American Cancer Society, about 242,000 new cases of prostate cancer will be
diagnosed and 28,000 men will die of prostate cancer this year30. Prostate cancer is slow
growing, and can be asymptomatic years before it is detected. As a disease of aging, it tends
to be diagnosed in men over the age of 60, causing pain, difficulty in urinating, problems
during sexual intercourse, and erectile dysfunction 31•
As previously stated, the prostate requires androgens in order to function properly32. These
androgens include testosterone, dihydroxytestosterone, and dehydroepiandrosterone.
Testosterone is made in the testes, dehydroepiandrosterone in the adrenal glands, and
dihydroxytesterone is converted from testosterone in the prostate ~. These androgens are
required in the prostate epithelium in order to promote growth and development. Loss of
androgen leads to a dramatic apoptotic death along with up regulation of TGFI3 ligands, and
Smads ~
2.2 Transforming Growth Factor/i (TGFfi)
Transforming growth factor beta (TGFf3) has been implicated in cell growth, migration,
tissue repair, inflammation, angiogenesis, metastasis, and tumorigenesis. TGFf3 has three
known isoforms (f31, 132, 133) with a 70% amino acid identity. TGF[31 consists of 390 amino
acids, while TGF132 and 133 consist of 412 amino acids ~ Latent dimeric forms are secreted
into the extracellular matrix and then cleaved by furin to form an active TGFJ3 signaling
molecule. TGFf3 contains 9 conserved cysteine residues which have highly conserved
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structural motifs that aide in the receptor binding specificity of the TGFf3 ligand. During the
canonical signaling process, TGFf3 ligand binds to its receptor, TGFI3 receptor II, sometimes
with the help of TGFI3 receptor III. The TGFI3 Receptor II is able to form a receptor complex
with other type I receptors such as ALK1, ALK2, and ALK5 and able to activate alternative
signaling pathways 36• The ALK1 or ALK2 receptors are capable of phosphorylating Smadi,
Smad5, or Smad8. ALK5 is able to phosphorylate Smad2 or Smad3 (see appendix Figure 3).
Receptor mediated Smads (1, 2, 3, 5, and 8) are then able to heterodimerize with Co-Smad
(Smad4) (see appendix Figure 4). Antagonist Smads include Smad6 and Smad7. Upon
phosphorylation by the receptor complex, Smad2 and Smad3 undergo heterodimerization
with Smad 4. This Smad dimer then translocates into the nucleus to interact with co
activators, co-repressors, and other transcription factors and binds Smad binding elements
(SBE) in order to affect gene transcription (see appendix Figure 5) ~ These genes play
roles in TGFf3 effects on cell growth, cell mobility, angiogenesis, growth arrest, apoptosis,
and cell morphology 36• TGFf31 null mice have been shown to exhibit cardiac and bone
abnormalities. The TGFf32 isoform has been shown to be involved in differentiation and
embryonic development and null mice for this isoform exhibit defects that include cardiac,
lung, limb, spinal column, eye, and inner ear defects. TGFI33 isoform is involved in
differentiation, embryonic development, and cellular adhesion and null mice for the 133
isoform exhibit bone development defects. Null mice for both TGFf32 and 3 are also
embryonic lethal, while null mice for TGF131 survive for about 15 days ~
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2.2.1 TGF/i receptors I, II, and II
As previously stated, the TGFI3 uses three receptors which are necessary for its actions.
Mutations in these receptors have been implicated in cancer and an alteration of TGFf3RI and
TGFI3RII is observed at the mRNA and/or protein levels38. In T-cell lymphomas, loss of
TGFI3RI correlated with a decrease in receptor II mRNA levels and growth39. In Human
keratinocytes (HKc) cells immortalized by human papillomavirus 16 DNA (HKc/HPV16),
TGFI3RI was shown to play a role in the progression of the loss of sensitivity TGFf3 effects
on growth. As these cells became TGFI3 resistant, the mRNA levels of TGFf3RI were
decreased, while the levels of TGFf3RII remained unchanged. This suggested that this loss of
TGFj3 sensitivity may be attributed to the loss of TGFf3RI expression40.
In stromal fibroblasts during mammary development, the TGFf3RII gene was
conditionally knocked out in mouse mammary fibroblasts, which led to abnormal mammary
ductal development. When the cells were transplanted with carcinoma cells, they promoted
growth and invasion41. Loss of the TGFf3RII has also been associated with a higher tumor
grade in prostate cancer42. Immunohistochemical studies on TGFf3 receptors were carried out
on thirty-two human prostate cancer samples and eight samples of benign human prostate.
Immunoreactivity for both type I and type II receptors were detected in the epithelial cells of
the benign human prostate tissues. Four out of thirty-two prostate cancer samples screened
was positive for TGFf3RII and eight samples for TGFj3RI. In contrast, all eight samples for
benign prostate tissue samples stained for both type I and type II receptors43. Knockout of
TGFI3RII expression in stromal cells resulted in the progression of adenocarcinoma within
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seven months. There was also a loss of TGFf3RII expression in 69% of human prostate
cancer associated stroma compared to 15% of benign stroma tissue samples44. There is also a
correlation between the loss of expression of TGFI3RI and TGFI3RII and increasing Gleason
score, clinical tumor stage, and serological recurrence in human prostate cancer tissues45.
Studies have shown TGFf3RIII functions as a co- receptor to increase ligand binding
to TGFf3RII, and a study in oral squamous cell carcinoma (OSCC) and oral leukoplakia
(OLK), demonstrated its role in carcinogenesis of oral mucosa. In this study, normal oral
tissues, OLK, and OSCC were obtained from one hundred thirty-eight patients; seven
primary human oral lines (CAF) and six primary fibroblast lines were established through
cell culture. Immunohistochemistry (IHC), quantitative RT-PCR, and Western blotting were
performed to assess the levels of TGFI3 receptors46. IHC signals for both TGFI3RII and
TGFI3RIII decreased in tissue samples with increasing disease aggressiveness and mRNA
and protein levels TGFI3RII and TGFf3RIII for both were down regulated in carcinoma
associated fibroblasts (CAF). The addition of exogenous TGFI31 also decreased the
expression of TGFf3RII and TGFf3RIII in carcinoma associated fibroblasts. This suggests
that loss of TGFI3RJII may have additional features in addition to ligand presentation47. This
provides more evidence that the disruption of TGFf3 receptors play a role in promoting tumor
metastasis.
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2.2.2 TGF/J regulation ofSmads
The activation of TGFJ3 results in the phosphorylation of specific R-Smads, Smad2,
and Smad3. The three dimensional structure of the TGFI3RI kinase domain with that of the
SARA (Smad Anchor for receptor activation) complex and Smads show that SARA is
required in order to bring Smads into close proximity within the ioop of the TGFf3RI kinase,
which determines the R-Smad specificity of the receptor 48 Smad proteins do not have
enzymatic activity, and small changes to the expression level of Smad protein can have a
dramatic effect on cellular responses. This is demonstrated by heterozygous Smad2/Smad3
mutant mice, which resulted in embryonic lethal phenotype. Studies using short hairpin
RNA (shRNA) system to silence Smad2 or Smad3 in non-tumorigenic rat prostate basal
epithelial cell line (NRP- 152) were used to analyze the effects of TGFf3 mediated apoptosis.
Tumors induced by silencing Smad2 and Smad3 were larger than those from silencing
Smad2 alone49. Another study using forty-nine tissue samples for prostate cancer and ten
benign prostate tissues showed that nuclear p-Smad2 and nuclear Smad4 were significantly
decreased in prostate cancer tissue samples when compared to benign tissue and normal
samples50. This demonstrates a role for Smad2 and Smad3 as a tumor suppressor in the
prostate.
Once the TGI3 receptor complex recruits R-Smads, it partners with the Co-Smad,
Smad4 to translocate into the nucleus where they activate downstream transcriptional
response51. Smad4 is only able to translocate to the nucleus when it is accompanied by R
Smads, whereas Smad2 and Smad3 can translocate to the nucleus in a Smad4 independent
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fashion ~. Examples of these Smad4 independent responses include the induction of
fibronectin and TGFI3 induced cell cycle arrest which are dependent on activation of Jun N-
terminal kinases (JNK) and extracellular signal related kinases (ERK), mitogen activated
protein (MAP) kinase pathways respectively 52•
2.2.3 TGF/i, Non- Smad Signaling Pathways
Downstream of the TGFf3 receptor signaling, it has been shown that R-Smads are
capable of crosstalk with other pathways in order to affect biological processes, independent
of Smad4. Mitogen activated kinase pathway (MAPK), plays an important role in cellular
signaling. The multiple MAP kinase pathways can lead to the downstream activation of
either ERK1 /2 or to stress activated proteins INK and p38 MAP kinase53. Mutations in this
pathway have been implicated in cancers especially in the activation of Ras, which is an
upstream activator of the ERK1/2 pathway54. TGFf3 also activates P13 kinase pathway
independently of Smad2/Smad3 activation55. Studies using immunoprecipitation
experiments have shown that TGFf3RJI associates with p85, which is a regulatory subunit of
P13 kinase. TGFI3RI association with p85 also requires TGFI3 stimulation56. P13 kinase
activation leads to phosphorylation of AKT. AKT1, AKT2, and AKT3 are the isoforms of
the serine/ threonine protein kinase B family ~ AKT1 and AKT2 have been observed in
many tumor types and also play a role in increased proliferation, survival, and glucose
metabolism, while AKT3 has been linked to mitochondrial biogenesis58’ 59~ The conversion
of PIP2 (phosphatidylinositol 4, 5, biphosphate) to PIP3 Q,hosphatidylinositol 3, 4, 5
trisphosphate) is catalyzed by P13K in order to phosphorylate AKT. Activation of AKT and
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phosphorylation requires binding of AKT, PDK1 and mTOR (mammalian target of
rapamycin) to PIP360. PTEN (phosphatase and tension homolog) acts as a tumor suppressor
to dephosphorylate PIP2 and PIP3. PTEN is inactivated or deleted in many cancers and is
induced or down regulated by TGFI3, depending on RAS activity61. Its role as a tumor
suppressor has also been linked to its interactions with p53. PTEN inactivation increases the
expression of MDM2 (murine double minute 2), a p53 repressor, and AKT activation62.
2.2.4 Role of TGF/J in Cancer
In normal epithelial cells, TGFf3 1 works through its signaling pathway to stop the cell
cycle at the G 1 stage in order to inhibit proliferation, induce differentiation, or promote
apoptosis. But, when a cell becomes metastatic, the tumor becomes more resistant to growth
inhibition and these cancer cells continue to proliferate in the presence of TGFI3. TGF~3
produced by advanced cancer cells then act on surrounding cells causing immunosuppression
and angiogenesis, which makes the cancer cells more invasive (see appendix Figure 6)63.
Although TGFI3 has been implicated in these processes, the mechanisms involved in the
transition from acting as a tumor suppressor in normal cells and switching to a tumor
promoter in malignant cells are unknown.
2.2.5.1 TGF/3 acts as a tumor suppressor
In normal epithelial cells, TGFI3 functions to inhibit proliferation. This proliferation
occurs through down regulation of maj or proliferative cell cycle components at the G1 phase
of the cell cycle64. TGFf3 induces CDK inhibitors such as p21(Cipl), p15, and p27 (kipi)
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which blocks cyclin and cyclin dependent kinases from phosphorylating retinoblastoma
protein (Rb), which allows the hypo- phosphorylated Rb to bind and sequester the E2F
transcription factor, thereby directly suppressing c-myc 65~ TGFf3 constrains cancerous
growths through suppression of c-Myc, Idi, 1d2, and 1d3. This expression of these cell cycle
factors are regulated by TGFI3 and Smad signaling pathway65.
2.2.5.2 p21 (CDKN1A)
p21 (CDKN 1 A) is a member of the Cip and Kip family of cyclin dependent kinase (CDK)
inhibitors, which also include p27. P53 acts as a tumor suppressor in order to inhibit
proliferation via p21 dependent growth arrest66. P21 has two main functions which are to
regulate the carboxyl-terminal PCNA binding domain and the amino-terminal CDK-cyclin
inhibitory domain. When p21 binds to PCNA, it competes for PCNA binding with DNA
polymerase-6 and other DNA synthesis associated proteins in order to inhibit DNA synthesis.
P21 is also able to inhibit CDK activity by blocking the phosphorylation of CDK1 and CDK2
in the activation segment67.
2.2.5.3 c-Myc
c-Myc (Myc) is a transcription factor which is mutated in many cancers, which leads to
the up regulation of many genes involved in proliferation. Activation of myc has been
implicated through various pathways including Wnt, TGFf3 and EGF (MAPKIERK), which
results in numerous biological effects6870. These effects include cell proliferation by up
regulating cyclins and down regulating p21, and cell growth by up regulating ribosomal RNA
and proteins. Myc null rat fibroblasts are viable but showed a severe retardation of
proliferation, a reduced rate of RNA and protein synthesis71.
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2.2.5.3 TGF/J’s Role in Apoptosis
TGFI3 induces apoptosis through the SMAD or DAXX (Death associated protein 6)
pathway. During TGF~ regulated apoptosis, Smads affect transcription factors including
activating mitogen activated protein kinase 8 pathway, triggering apoptosis72. TGFI3 may
also cause apoptosis through direct association with death associated protein 6 (DAXX
adapter protein), which is a protein associated with the Fas receptor that mediates activation
of Jun amino-terminal kinase (JNK) and programmed cell death induced by Fas ~
2.3 TGF/3 acts as a tumorpromoter
In normal epithelial cells, TGFI3 is known to act as a tumor suppressor, but during cancer
progression, this growth inhibitory effect is lost due to alterations within the TGFf3 signaling
pathway74. These alterations result in the additional production of TGFf3 in these tumors and
promote tumor progression through enhancing cell invasion, migration, and evasion of
immunity. These functions play an important role in TGF~3 growth inhibitory the metastatic
process
Cancer cells tend to lose this response to TGFI3 abilities through alterations in the Smad
transcriptional regulation which mediate cytostatic gene responses76. In a breast cancer
model system, it was shown that TGFI3 cytostasis was induced when proliferating factors
such as p15 or c-myc were unable to respond to TGFf3 growth inhibitory abilities. This
means that the loss of these two genes render resistance of TGFf3 effects on proliferation.
When tumors occur in the body, T lymphocytes are used as natural killers in order to
eliminate cancer cells. Cancer cells producing TGF~3 take advantage of this potent
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immunosuppressive function and dampen this surveillance system77. This allows for tumors
to grow and allow angiogenesis to occur.
2.4 Angiogenesis
In angiogenesis, endothelial cells and vessels enable a fast growing tumor to receive the
nutrients and oxygen needed for growth. Hypoxic conditions along with TGFI3 have been
shown to induce levels of VEGF mRNA through activation of hypoxia inducible factor 1
(HIF 1) and Smad proteins74. TGFf3 also regulates the expression, activity, and secretion of
matrix metalloproteases MMP-2 and MMP-9 and down regulate the expression of the
protease inhibitor TIMP in the tumor and endothelial cells. Through these mechanisms,
TGFI3 enhances the migratory and invasive properties of endothelial cells required for
angiogenesis78.
2.5 Invasion and Metastasis
TGFf3 is able to promote migration and invasion of cancer cells. In order for cells to
become motile, they must undergo a loss of cell-cell contacts and acquisition of fibroblastic
or mesenchymal characteristics. This process, also known as EMT (epithelial to
mesenchymal transition), is promoted by TGF~ by a combination of Smad dependent
transcriptional events and also by Smad independent effects on cell junctions79. Reports have
shown that TGFf3 signaling promotes the loss of epithelial characteristics such as a loss of E
cadherin, and increased mesenchymal characteristics such as secretion of vimentin and
fibronectin. TGFf3 signaling through Smad mediated expression of HMGA2 (high mobility
group A2) has been shown as important for Snail and Slug induction. These zinc-finger
transcription factors are known to repress E-cadherin 36~ These mesenchymal cells can also
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play a role in modulating the components of the extra cellular matrix (ECM). The ECM is
essential for growth, fibrosis, and wound healing. During EMT, the ECM is remodeled
through the production of serine- threonine proteases and matrix metalloproteinase proteins
(MMP). These MMPs function to modulate tissue remodeling of processes including
metastasis 80 MMP-2 and MMP-9 are two primary forms thought to be involved in invasion.
TGFI3 was shown to strongly induce MMP-2 and MMP-9 expression in a Smad3 and Smad4
dependent manner, inducing invasion of MCF 1 0-Ras- transformed (pre) malignant
derivatives of MCF 10 cells8’. Immunohistochemical staining in breast carcinomas have also
correlated TGFI3 induced invasion and metastasis through the modulation of MMP-2 and
MMP-982. In human fibroblast, electrophoretic mobility shift assays revealed that AP-i
transcription factors played major roles in mediating MMP-13 activation by TGFf383. Studies
comparing growth and ECM responses to TGFf3 in six metastatic and six primary tumor
derived cell lines were used in mouse model of prostate cancers to assess MMP levels. The
results showed increased quantities of secreted TGFf3s, loss of growth inhibition, an increase
of MMP-9, and stimulation of plasminogen activator-i (PAl-i)84. In prostate cancer cells,
exogenous TGFI3 also increases the secretion of plasminogen activator (PA-i), which
promotes extracellular degradation and is correlated with a more aggressive phenotype85.
PAl- 1, is a serine protease inhibitor that acts as an inhibitor of tissue plasminogen activator
(tPA) and urokinase (uPA), which are the activators of plasminogen86. Stimulation of PC3
cells with TGFI3 has also resulted in an increase in PAl-i secretion in prostate cancer
studies87. This process of inducing mesenchymal characteristics and stimulating ECM
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degrading products in order to increase cell mobility, and loss of cell adhesion, initiates
metastasis.
During tumor progression, tumors derived from epithelial cells become mobile, as
previously stated, and acquire mesenchymal characteristics. This facilitates intravasation of
tumor cells into the blood or lymph vessels and the formation of distant metastasis. In
prostate and breast cancer, bone metastasis is prominent in response to TGFI3 signaling. The
microenvironment of the bone is also rich in growth factors, such as TGFf3. This enables
metastatic cells to thrive and this tissue releases these cytokines that in turn activate
osteoclast differentiation. This activation causes osteoclast to degrade the bone matrix and
release its storage of TGFJ3. This process also stimulates the production of parathyroid
hormone- related protein (PTHrP), interleukin- 11, and connective tissue growth factor
(CTGF). In turn, these factors stimulate the release of RANK ligand (RANKL), which
mediates osteoclast mobilization88. This cycle of metastasis is continuous, leading to an
increase of more TGF~, and more bone degradation.
2.6 Inhibitor ofDifferentiation Proteins
Id, inhibitor of differentiation, proteins are a family of proteins that heterodimerize with
basic-helix-loop-helix (bHLH) transcription factors in order to inhibit DNA binding of bHLH
proteins. These proteins contain the HLH- dimerization domain, but lack the basic DNA
binding domain, and thus negatively regulate transcription when they heterodimerize with
bHLH proteins (see appendix Figure 7)89 There are two main groups of bHLH proteins. E
proteins, also known as class A proteins, which include those encoded from splice transcripts
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from E2A (E12, E47, and E2-5), E2-2/ITF2 and HEB/HTF4 genes. Class B proteins include
MyoD, myogenin, NeuroD/BETA2, MASH, HAND, and TAL. Dimerization is necessary for
DNA binding and transcriptional activity of these proteins. This activity occurs through the
dimerization of class B bHLH proteins forming heterodimers with class A bHLH proteins.
The basic region is required for DNA binding through a region that includes a specific motif
called the E-box (CANNTG). Ids lack this basic DNA binding domain. Id proteins bind to
both class A and class B proteins in order to inhibit their ability to bind to DNA90. Idi, 1d2,
1d3, and 1d4, are the four known Id isoforms and are small proteins of approximately l3kDa-
2OkDa. Following mitogenic stimulation, Id proteins are rapidly induced in about 30 to 60
minutes as part of an immediate early response cascade91. Heterodimers with bHLH proteins
extends the life of 1d3, while enhancing the degradation of its heterodimeric partner91.
Dimerization of Idi with MyoD has also been shown to protect Idi protein from proteasome
degradation 92
Id proteins function at multiple stages in the cell cycle by modulating the transcription of
target genes by directly interacting with non bHLH proteins such as pRB, ETS transcription
factors, and PAX transcription factors9395. E2A is the most common bHLH protein partner
of Id proteins. Idi and 1d3 specifically, are able to bind and inhibit the binding of these
proteins. E2A-null mice result in a significant increase in T-cell lymphoma, and an increase
in neonatal death96. E2-A proteins have also been shown to be involved in the regulation of
the expression of p21 in HeLa cells leading to growth arrest97. Id proteins act as positive
regulators of cell growth and their functions are required for cell cycle progression. Our
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studies have indicated that Idi and 1d3 silencing resulted in loss of proliferation in prostate
cancer cells’2.
2.6.1 Idi
Idi has been implicated as a mediator of tumor cell migration and been shown to
correlate with enhanced malignant potential of breast, prostate and ovarian tumors13’ 14, 98, 99~
Idi also promotes tumor cell migration in non-small cell lung cancers (NSCLC). In these
cells, constitutive expression of Idi significantly increases tumor cell migration, without
affecting proliferation 15~ In studies with paraffin embedded tissue specimens from two
normal prostates, twelve benign prostatic hyperplasia (BPH) forty-three prostate cancers
(PCa) were studied and Idi detected by immunofluorescence. Prostate cancer specimens had
an up regulation of Idi while showing weak expression in BPH’°°. Idi has also been shown
to play a role in radial growth phase melanomas. There were elevated protein levels which
correlated with increased promoter activity and growth’°’. In bone marrow, Idi mRNA was
significantly associated with lymph node metastasis. In these cells located in bone marrow
of metastatic cancer, Id 1 stained strongly when compared to healthy samples’°2. Our studies
have shown that loss of Idi is indicative of loss of proliferation’03. We have also shown that
over expression of Id 1 in ventral prostate epithelial cells (Id 1 -RPE) was shown to promote




Studies have shown that over expression of 1d2 in ovarian and breast cancer cells did not
alter proliferation, but induced the invasion potential of ovarian and breast cancer cells ~
1d2 has also been linked to apoptosis and association with retinoblastoma protein’05.
Silencing of 1d2 in colorectal cancer cells led to decreased levels of cyclin Dl and increased
levels of cell cycle inhibitory protein p21. This effect was accompanied with decreased cell
survival and increased cleavage of the anti- apoptotic protein, caspase 7106• 1d2 expression is
also an essential aspect of lymphatic organ development and 1d2 null mice lack lymph nodes
and Peyers patches’°7.
2.6.3 1d3
A recent study indicated that 1d3 protein was highly expressed in prostate cancer tissue
samples, which correlated with an increased Gleason score 22 In lymphomagenesis, a
functional genomic screen in p27 (+1-) mice showed that 1d3 was a transcriptional suppressor
of p~7~O8• In thyroid cancer studies 1d3 was significantly increased in tumors when
compared to normal thyroid tissue. This increase of Id3 was associated with triggering the
angiogenic switch in thyroid tumorigenesis’°9. Over expression of Id3 has also been
associated with enhanced proliferation of vascular smooth muscle cells (VSMC). In contrast,
1d3 antisense transfection inhibited proliferation induced by platelet- derived growth factor




Idl, 1d2 and 1d3 are expressed highly in prostate cancers while 1d4 expression is
inversely related to development of prostate cancer12’ 13 Our studies have also revealed that
1d4, which is down regulated in various cancers through DNA hypermethylation, acts as a
tumor suppressor by increasing apoptosis and decreasing proliferation when expressed in
prostate cancer cells23.
2.7 TGF/J1 and Id cross- talk
Previous studies have shown TGFI31 to act as an upstream effector of Idi expression in
normal prostate epithelial cells 24 TGFI3 1 has been shown to induce an early expression of
Idl which is followed by a down regulation of Idi levels after prolonged exposure to TGFI3
~ Inactivation of Id 1 in these cells increased their sensitivity to TGFI3 1 induced growth
arrest and up regulation of p21/WAF1/CIP1 and p27/KIP1 protein expression”2. Loss of Idi
induced by TGFf31 has also been shown to be mediated by Smad3 signaling in breast and
colorectal cancer cell lines; Smad3 and Smad4 were shown to bind directly to the Idi
promoter 25 Studies have also shown that 1d3 is a mediator of TGFf3 effects on lymphocyte
survival through inhibition of B lymphocyte progenitor growth 113 While TGFI3 effects on
Idi expression and its role in cell proliferation has been investigated in normal prostate cells,
very little is known about the role of Ids in TGFf3 signaling during its transition from tumor
suppressor to a tumor promoter. The purpose of the present study was to investigate
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comparative roles of Id 1 and 1d3, which are significantly elevated in prostate cancer cells, in




Recombinant human TGFI31 was purchased from R & D systems (Minneapolis, MN). The
antibodies against Idi, 1d3, fibronectin, and p27 were purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA). The antibody against p21 was purchased from Epitomics, Inc.
(Burlingame, CA). The antibodies against Ki-67, PAl-i, and PCNA were purchased from BD
Biosciences, Inc. (San Jose, CA). Anti-13-Actin (clone AC-15) antibody was purchased from
Sigma-Aldrich (St. Louis, MO). Anti-rabbit IgG HRP was purchased from Biosource
(Camarillo, CA). Anti-mouse IgG HRP was obtained from Promega (Madison, WI).
Cell Lines and Cell Culture
Several cells lines derived from human normal prostate epithelial cells and prostate cancer cells
were used in this study (see appendix table 1). All cell lines were obtained from American Type
Cell Culture Collection (Rockville, MD). Cells were cultured in recommended growth media at
37°C with 5% CO2 and 100% humidity as described earlier114 To determine the effects of TGFI3
on Id proteins, cells were cultured in 10 cm2 dishes to approximately 80% confluency and then
treated with TGFI31 (5ng/ml) for specific time points. For some experiments, cells were pre
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treated with TGFI3 Receptor I inhibitor (SB43 1542; 5~tM), Smad3 Inhibitor (SIS3; 3~tM), P13K
inhibitor (LY294002) or MAPK inhibitor (PD098059) for lh prior to TGFI31 treatment.
Inhibitors
TGFI3 Receptor I inhibitor (SB43 1542; 5 ~tM) is a selective inhibitor of the transforming growth
factor-13 (TGF-~3) type I receptor activin receptor-like kinase ALK5, and its relatives ALK4 and
ALK7. It suppresses TGF-f3-induced proliferation of human osteosarcoma cells 115 Smad3
Inhibitor (SIS3; 3~M) inhibits TGF-f3 1-dependent Smad3 phosphorylation and Smad3-mediated
cellular signaling with no effect on Smad2, p38 MAPK, ERK, or P1 3-K signaling 116 P13K
inhibitor (LY294002) was shown to act in vivo as a highly selective inhibitor of
phosphatidylinositol 3 (P13) kinase. When used, it specifically abolished P13 kinase activity but
does not inhibit other lipid and protein kinases such as P14 kinase, PKC, MAP kinase or c-Src.
117 MAPK inhibitor (PD098059) is an inhibitor of mitogen-activated protein kinase kinase
(MKK / MEK). It acts by binding to the inactivated form of MEK, thereby preventing its
phosphorylation by cRAF or MEK kinase. It inhibits cell growth and proliferation in acute
myelogenous leukemia (AML) cell lines; causes G1 arrest by blocking p53-dependent p21
induction 115
RNA isolation, eDNA synthesis and RT-PCR
Total RNA was isolated from the cells using TRIzol (Invitrogen) followed by chloroform
extraction and isopropanol precipitation and quantified by optical density reading at 260 nm as
previously described 118 Two micrograms of total RNA were reverse transcribed as previously
25
described 118 RT-PCR reactions were performed in Rapid Cycler thermal cycler (Idaho
Technology, Salt Lake City, Utah) and were performed according to established procedures 118
Gene encoding ribosomal protein L19 was used as internal control. The oligonucleotide pair
used to amplify L- 19 mRNA were synthesized as described previously 118 All other gene-
specific primers were designed with the assistance of Beacon Designer 5.0 (PremierBiosoft
International, Palo Alto, CA) which was set to exclude regions of cross-homology against the
non-redundant set of human genes from GenBank, EMBL, and DDBJ database sequences) and
to exclude regions of significant secondary RNA structure. Primer sets were designed to span
long introns to avoid potential amplification of genomic DNA. Primers for various genes were
used for this study (see appendix Table 2). The PCR products were visualized on 1-2% agarose
gels stained with ethidium bromide (Amresco, Solon, and OH). Relative amounts of PCR
products were estimated by digital densitometry as previously described’14 Expression levels of
target genes were normalized to the expression of Li 9 mRNA.
Western blot analyses
After specific treatments, the cells were washed twice with ice-cold phosphate-buffered saline
(PBS) and lysed in lysis buffer as previously described 118 Protein concentrations were
determined by the Lowry HS assay using the Bio-Rad DC Protein Assay kit (Bio-Rad) according
to the instructions provided by the manufacturer. Cell lysates were mixed with Laemmeli’ s
buffer (62.5 mM Tris, pH 6.8, 2% SDS, 5% f3-mercaptoethanol and 10% glycerol) and individual
samples (25- 50 ~‘g protein) were subjected to SDS-PAGE in 7.5% or 10% gels and transferred
to PVDF membranes (Millipore, Billerica, MA). The membranes were blocked at room
26
temperature for lh in phosphate buffered saline (PBS) containing 5% skimmed milk. The blots
were then incubated with appropriate dilutions of primary antibodies (Idi ,1:250; 13,1:250; p2 1,
1:250; Ki-67, 1:500; PCNA, 1:1,000; p27, 1:500) overnight at 4°C. After washing, the blots
were incubated with anti-rabbit immunoglobulin coupled to horseradish peroxidase (dilution
1:10,000) for lh. The blots were developed in ECL mixture (Pierce Biotechnology, mc,
Rockford, IL) for 1 mm, exposed to an X-ray film and visualized by autoradiography. Western
blots for f3-actin (antibody dilution 1:10,000) were carried out in parallel as loading controls. The
relative intensities of specific protein bands were determined by QuantityOne image analysis
software.
Transfection with Idi and 1d3 SiRNA
For siRNA transfection, cells were seeded in a 6-well plate at a density of 2 x 1 0~ cells per well
in 2m1 antibiotic-free normal growth medium supplemented with 5% FBS. The cells were
incubated at 37°C in a CO2 incubator overnight. The siRNA transfection solutions were
prepared according to the instructions provided by the manufacturer (mdl, sc-29356; 1d3, sc
38002; Control siRNA-A, sc-37007; transfection reagent sc-29528; Santa Cruz Biotechnology).
One ml of siRNA transfection medium was added to the cells for 6h. Then, an additional 1 ml of
normal growth medium containing 3 times the normal serum concentration was added for an
additional 24h. At this point, the transfection medium was aspirated and replaced with fresh
normal growth medium. The proliferation assays and! or other treatments of the cells were
carried out 24 h after the addition of fresh medium.
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Cell Prol~feration Assay
Cell proliferation analyses were performed using 3 -(4, 5 -dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. PZ-HPV-7, PC3 and DU145 cells were seeded in
96-multi well plates at a density of 5 x 1 ~ cells! well overnight. Cells were then treated with
TGFf31 (5 ng!ml) in the presence of 5% FBS for 48 h. MTT assay was performed using
CellTiter 96 Non-Radioactive Cell Proliferation Assay (Promega) following manufacturer’s
instructions.
FA CS Analysis
Cells were plated with 5% FBS at a density of 2 x lO5cells! well in a 6 well plate. On day two,
the cells were serum starved for 24 hours prior to treatment. Then, 5ng/ml of TGFI3 1 was be
added and incubated for 24 hours. Cells were trypsinized, resuspended in imi of 70% ethanol,
and placed in -20°C freezer overnight. The next day, the cells were centrifuged and resuspended
in lml of a RNAse (1 .25 pJ!ml), Propidium Iodide (900p1) Dulbecco’s Phosphate Buffered Saline
(DPBS) mixture. The cell cycle profiles were then analyzed using BD Accuri Cytometer (Ann
Arbor, MD) following manufacturer’s instructions.
Cell Migration Assay
In vitro cell migration assay was performed using 24-well trans-well inserts (8 jim; ref. 26).
Briefly, cells were washed once with MEM and harvested from cell culture dishes by EDTA
trypsin into 50 ml conical tubes. The cells were centrifuged at 500 x g for 10 minutes at room
temperature; the pellets were re-suspended into MEM supplemented with 0.2% bovine serum
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albumin at a cell density of 3 x 1 ~ cells/mi. The outside of the trans-well insert membrane was
coated with 50 ~il of rat tail collagen (50 j~tg/m1) overnight at 4°C. The next day, aliquots of rat
tail collagen (50 ~t1) were added into the trans-well inserts to coat the inside of the membranes.
The inserts were left to stand for 1.5 h at room temperature before being washed thoroughly with
3 mL of MEM. Chemoattractant solutions were made by diluting TGFf31 (5ng/ml) or EGF (3
ng/ml) into MEM supplemented with 0.2% bovine serum albumin. MEM containing 0.2%
bovine serum albumin served as a control medium. EGF was used as a positive control. Control
and chemoattractant solutions (400 pi) were added into different wells of a 24-well plate.
Aliquots of 100 ~.il cell suspension were loaded into trans-well inserts that were subsequently
placed into the 24-well plate. The trans-well insert-loaded plate was placed in a cell culture
incubator for 5 h. At the end of the incubation, trans-well inserts were removed from the plate
individually; the cells inside trans-well inserts were removed by cotton swabs. The cleaned
inserts were fixed in 300 jiL of 4% paraformaldehyde (pH 7.5) for 20 minutes at room
temperature. Cells on the outside of the trans-well insert membrane were stained using HEMA 3
staining kit (Fisher Scientific, Inc.). The number of stained cells was counted in four non-
overlapping low-power fields of a light microscope, and the average number of cells reflected
the cell migration status in each trans-well insert. To avoid experimental bias, a systematic
random sampling technique was applied in the selection of representative fields, in which sample
preparation and handling was executed by different persons. Results were expressed as
migration index, which is defined as the average number of cells per field for test substance / the
average number of cells per field for the medium control. Each experiment was repeated at least
three times using a different cell preparation”9
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DNA Synthesis- 3H Thymidine Incorporation
Cells were cultured to the density of 8x104/ml (40,000/ 500p1) and 0.5ml of cell suspension was
added to each well of a 24-well plate, and incubated overnight. Medium was then replaced with
0.5m1 of serum free culture medium for 24h. Fresh medium (including 5%FBS) along with
different treatments (carried out in triplicate) was added for 1 8h at 3 7°C. The culture medium
was then replaced with fresh medium (without FBS) containing 3H-thymidine (1 iiCi/ml) and
incubated at 37°C for 4h. Medium was then aspirated and 500 jil of cold distilled water added.
Cells were then disrupted by sonication, disrupted, and the cell lysates transeferred to a Whatman
DE8 1 filter paper. The DNA bound filter discs were washed twice each time with 1 .Oml of
distilled water. The filters were then transferred to scintillation vials containing 4.0 ml of
scintillation fluid, and the Beckman scintillation counter was used to determine radioactivity.
Scratch WoundAssay
Scratch wound assay was carried in a 6-well plate containing cells that had reached 60-70%
confluency. After removal of the medium, two scratches were made per well using a 200 jil
pipette tip. Cells were then washed with the fresh medium, and then appropriate treatments were
added for 48h. Pictures were taken using a microscope with lox objective.
Statistical Analysis
Experiments were performed at least 2 times using different cell preparations. Data from
representative experiments are shown in the figures. The significance of the differences among
treatments was determined by paired t- test, and One Way Analysis of Variance.
CHAPTER FOUR
RESULTS
4.1 Basal Expression ofIdproteins
We have shown the mRNA and protein expression levels of TGFI3 isoforms and receptors
in prostate epithelial and prostate cancer cell lines 120 Using the same approach, Inhibitor of
Differentiation (Id) isoforms 1 and 3 were determined in various cell lines. Previous studies
have implicated Idi and 1d3 in proliferation, while 1d2 has been more associated with apoptosis
and 1d4 as a tumor suppressor’°3. Based on these studies, we chose to focus on Idi and 1d3
isoforms were used for further experiments. We determined the steady state levels of Idi and
1d3 mRNA and protein in prostate and prostate cancer cell lines. Total RNA and protein were
collected from PZ-HPV7, RWPE-1, RWPE-2, DU145 and PC3 cells and analyzed by RT-PCR
(see appendix Figure 8) and Western blotting (see appendix Figure 9). Both the mRNA and
protein for Idi and 1d3 were expressed in all cell lines. Studies have also shown that Ids are
induced in the presence of serum121. Since the majority of our cell lines are grown in the
presence of serum, we reduced serum to determine if the mRNA or protein levels of Idi or 1d3
were comparable to levels in cells with serum present. Prostate cell lines were serum starved for
six hours prior to RNA or protein preparation. Serum starved cell lines showed a dramatic
difference when compared to the cell lines in the presence of serum. Idi and 1d3 mRNA were
increased in prostate cancer cell lines when compared to normal prostate epithelial cell lines (see
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appendix Figure 10). Similar results were seen on the protein levels of Id 1 and 1d3, which
increased in prostate cancer cell lines (see appendix Figure 11). This also correlated with NCBI
GEO profiles of Idi and 1d3 expression in androgen independent cell lines (see appendix Figure
12). Serum contains growth factors, which in turn induced Id proteins.
4.2 TGF/J effects on Idproteins
To determine the effects of TGFf3 1 on Ids, normal prostate epithelial cell line PZ-HPV7
and prostate cancer cell lines DU145 and PC3 were cultured under normal conditions over night.
The following day, cells were serum starved in 0.1% FBS for 2h. Exogenous TGFI3 1 (Sng/ml)
was added at 0, 1 and 8 h time points. After treatment, cells were lysed, mRNA or protein
extracted and analyzed for RT-PCR or western blotting analysis, respectively. RT-PCR analysis
showed that Idi mRNA levels were induced in all three cell lines after treatment with TGFf3 after
lh. This is expected as Ids are shown to be immediate early response genes (see appendix Figure
13). Similar effects of TGFf31 were also observed on Idi protein levels (see appendix Figure
14). Interestingly, by 8h, Idi levels were decreased in PZ-HPV7, and DU145 cells, but not in
PC3 cells. Idi levels in PC3 cells remained stably induced at both the mRNA and protein levels.
Using the same cell preparations, we assessed the mRNA and protein levels of the 1d3 isoform
upon TGFf31 stimulation.. RT-PCR analysis showed that 1d3 was induced at lh in all cell lines
and remained stably induced up to 8h at the mRNA (see appendix Figure 15) and protein levels
(see appendix Figure 16). LNCaP cells treated with TGFf31 had no effect on Idl or 1d3 mRNA
levels (see appendix Figure 17). This is expected since LNCaP cells lack the TGFf3RII therefore,
exogenous TGFJ31 is unable to activate the TGFf3 signaling pathway in these cells’22.
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Longer incubation periods were then assessed to observe long-term changes in Id protein
expression in response to TGFI31 treatment. After prolonged exposure (24h) to TGFj31, Idl
mRNA levels decreased significantly in both PZ-HPV-7 and DU145 cells, but not in PC3 cells
(see appendix Figure 18). 1d3 mRNA levels remained stably induced in all cell lines at later time
points as well. We next investigated TGFf31 effects on steady-state levels of Idi and 1d3 proteins
in PZ-HPV7, DU145 and PC3 cells. TGFj31 treatment on protein levels exhibited similar
changes in response to TGFf3 1 treatment as seen at the transcriptional level in all cell lines (see
appendix Figure 19). TGFf3lsignificantly increased (2 to 4 fold; p<O.O5) levels of Idl and 1d3 in
all cell lines after 1 h of treatment. After prolonged exposure (24h) to TGFf3 1, Id 1 protein levels
declined significantly (p<O.O1) in PZ-HPV7 and DU145 cells but not in PC3 cells. In contrast,
Idi levels in PC3 cells increased 2.5-fold at lh and remained high after 24h of TGFf3 treatment.
TGFf31 treatment also caused a significant increase (2-3 fold; p<O.O5) in 1d3 protein levels in all
three cell lines, which remained elevated until after 24h. This suggests that TGFf3 exerts
differential effects on these two isoforms of Id proteins.
We studied the effects of TGFf32 and TGFf33 on Idl, 1d2, 1d3, and 1d4 expression in
DU145 prostate cancer cell line. Cells were treated with exogenous TGFf32 (5ng/ml) or TGFf33
(5ng/ml) for lh and 8h, and RT-PCR was used to analyze any change in the mRNA levels of Ids
(see appendix Figure 20). Both TGFj3 isoforms had effects on Idi and 1d3 expression, which
were similar to those of TGFf3 1. Id land 1d2 were induced at early time points and down
regulated at later time points, whereas 1d3 and Id4 levels were induced and remained stably
induced at later time points. In order to see comparative expression of Ids, both DU145 and PC3
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prostate cancer cell lines were treated with exogenous TGFf33 (5ng/ml) and analyzed for protein
levels of Idl and 1d3 (see appendix Figure 21). TGFf33 had an effect on Idl and 1d3 protein
levels which were similar to those of TGFI31. In DU145 cells, Idi protein levels were induced at
early time points and down regulated at later time points. 1d3 protein levels, however, were
induced and remained stably induced at later time points. Both Idl and 1d3 protein levels
remained stably induced in PC3 cells.
These results show that TGFf31 is able to elicit a biphasic response on Idi in normal
prostate epithelial cell line PZ-HPV7 and prostate cancer cell line DU145, but not in PC3 cells.
TGFf31 was able to stably induce 1d3 in all three cell lines. We also showed that TGFf3 isoforms
exert similar effects on Id proteins in these cell lines.
4.3 Early Induction ofIds by TGF/? is TGF/JRI Mediated and Smad3 dependent
To determine optimal dosage of TGFf31 on DU145 prostate cancer cell line, a dose-
dependent response was studied. DU145 cells were treated with TGFf3lat various doses up to
5ng/ml. The effects of TGFf3 1 on early induction of Id 1 and 1d3 expression were indeed dose
dependent (see appendix Figure 22) and maximum increase was observed after treatment with 5
ng/ml of TGFf3 1. The 5ng/ml dose was used for future experiments.
To ensure that TGFf31 effects on Ids were regulated by the canonical signaling pathway,
DU145 cells were pre-incubated with an inhibitor of TGFI3-RI (SB3 1542) for lh. Idl and 1d3
expression was induced by TGFJ3 1 treatment; however TGFf3RI inhibitor blocked these effects
(see appendix Figure 23).
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To determine whether differences in TGFI3 1 effects in different cell lines were due to the
inability of TGFI31 to induce receptor mediated phosphorylation of Smad proteins, we
determined the effects of TGFI31 on p-Smad 3 levels in PZ-HPV7, DU145, PC3 and LNCaP
cells (see appendix Figure 24). PZ-HPV7, DU145, PC3, and LNCaP cells were treated with
exogenous TGFI3 1 (5ng/ml) at different time periods and total cell lystate were analyzed by
western blotting for levels of p-Smad3. TGFf31 induced phosphorylation of Smad3 in PZ-HPV7,
DU145 and PC3 cells in a time dependent manner.
DU 145 cells were then treated with TGFf3 in the presence or absence of Smad3 inhibitor
(SIS3). This inhibitor blocked TGFj3 effects on expression of both Idi and 1d3 (see appendix
Figure 25). These results suggest that Idi and 1d3 are both TGFI3RT and Smad3 dependent. Both
P13K inhibitor (LY294002) and MAPK (PD98059) inhibitor had no effect on TGFf3 induced Idi
and 1d3 expression in DU145 cells (see appendix Figure 26).
4.4 TGF/J effects on Proliferation and Migration
TGFf3 is known to act as a tumor suppressor in the earlier stages of the disease and as a
tumor promoter in the later stages including differential effect on cell proliferation depending on
the context of the cell43. Therefore, we first studied the effects of TGFE3 1 on proliferation in cell
lines derived from normal prostate epithelial cells (PZ-HPV7 and RWPE- 1) and prostate cancer
derived (DU 145, PC3, LNCaP) cells using MTT Assay and Thymidine incorporation. Results
indicated that TGFJ31 caused a dose dependent decrease in proliferation in PZ-HPV7 cells (see
appendix Figure 27). TGFf3 also inhibited proliferation in DU145 cells, an effect that was
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similar to its effect on normal epithelial cells, but had no effect of PC3 cells and LNCaP cells.
TGFI3 1 also inhibited proliferation of RWPE- 1 prostate epithelial cells (see appendix Figure 28).
In normal epithelial cells, TGFI3 up-regulates cyclin dependent kinase inhibitors (CDKI)
p21 and p27, causing a G1 phase arrest in the cell cycle leading to decreased cell proliferation 64
To determine whether TGFf3 effects on Id 1 and 1d3 correlate with the expression of these cell
cycle regulators, the expression of both p21 and p27 were determined in cell lines with and
without the presence of exogenous TGFI31. PZ-HPV7, DU145, and PC3 were treated with
exogenous TGFI31 (5ng/ml) for lh and 24h, protein extracted, and analyzed by western blotting
to assess the levels of p21, p27, myc, PCNA, and Ki-67. p21 expression was undetectable in
untreated PZ-HPV7, DU145 and PC3 cells (see appendix Figure 29). Treatment with TGFI31 for
1 h did not influence p21 expression in these cells. However, 24h after the treatment, there was a
significant increase in the levels of p21 in PZ-HPV7 and DU145 cells which correlated with
decreased levels of Idl. In PC3 cells p21 levels were undetectable at all time points. There was
also no change in p27 levels in all three cell lines. 1d3 levels remained high in response to
TGFI31 in all cell types at both time points and did not correlate with changes in p21 levels.
Other proliferation markers, including proliferating cell nuclear antigen (PCNA), myc, and Ki-67
were also decreased in DU 145 cells after treatment with TGFJ3 1 (5ng/ml) for 24h (see appendix
Figure 30).
We then studied the effects ofTGFf3l on migration of prostate cancer cells (see appendix
Figure 31). As previously shown, DU145 cells did not exhibit migratory behavior in the
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presence of TGFI3, but did display migratory capabilities in the presence of epidermal growth
factor (EGF). However, PC3 cells migrated in the presence of both TGFI31 and EGF’20’ 123, 124
4.5 Loss ofIdi or 1d3 effects on Prohferation
To determine whether reduced intracellular levels of Idi are indeed responsible for
growth inhibitory effects of TGFj3 1 on cell proliferation, we determined the effects of TGFI3 1 on
cell proliferation after knock-down of endogenous Idl and 1d3 in PZ-HPV7, DU145, and PC3
cell lines. After knock down confirmation (see appendix Figure 32), proliferation assay were
used including MTT assay, Thymidine incorporation, cell counting, and/or FACs analyses. Cell
counting revealed that knock down of Idi or 1d3 alone inhibited proliferation of PC3 prostate
cancer cells. This correlated with previous studies which show that loss of Idi or 1d3 is able to
inhibit proliferation’03. Knock-down of endogenous Idi through siRNA resulted in a significant
reduction of proliferation in PZ-HPV7, DU145 and PC3 cells. Whereas TGFI31 induced a
further reduction in cell proliferation in PZ-HPV7 and DU145 cells, it had no additional effect on
proliferation in PC3 cells. Knock down of 1d3 also resulted in significant decrease in
proliferation in both DU145 and PC3 cells. There was no additional effect of TGFI31 on
proliferation of DU145 and PC3 cells treated with 1d3 siRNA. FACS analysis was used to
determine whether these effects were due to cell cycle regulation (see appendix Table 3). The
results showed that TGFI31 treatment and Idi knock-down, but not 1d3 knock-down, in DU145
cells decreased the number of cells entering the S phase of the cell cycle.
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Knock-down of Idi also increased p21 protein levels in DU145 prostate cancer cells, but
not PC3 prostate cancer cells (see appendix Figure 36). Since we previously showed that TGFJ3 1
is able to down regulate Ki-67 expression in DU145, we next repeated this experiment upon the
addition of Id 1 siRNA. In prostate cancer cell line DU 145, Id 1 siRNA decreased the protein
levels of Ki-67, which was further decreased after treatment with TGFI3 (see appendix Figure
37). This suggests a possible role of Idl, but not 1d3 in TGFf3 mediated effects on proliferation.
4.6 Idi and 1d3 Roles in TGFJI Mediated Cell Migration
Since previous studies have implicated TGFI3 in increased cell motility and cell invasion,
we studied the roles of Id 1 and Id3 in TGFI3 effects on migration of prostate cancer cell lines
DU145 and PC3 using scratch wound and migration assays. Scratch wound assays were used to
first determine the role of Idl and Id3 on TGFj31 effects on cell motility. For these treatments,
DU145 and PC3 prostate cancer cells were treated with siRNA against Idl or Id3 as previously
described, scratched using a 200 jil tip, and then treated with exogenous TGFf31 (5ng/ml) for 48h.
DU145 prostate cancer cells were unresponsive to TGFI31 effects on cell motility (see appendix
Figure 38). Both Idl and Id3 siRNA had no effect on DU145 prostate cancer cell movement.
Upon TGFI31 treatment, PC3 prostate cancer cells moved as to close the wound (see appendix
Figure 39). Idi or 1d3 siRNA blocked these TGFf31 mediated effects. TGFI33 (Sng/ml) was also
shown to induce PC3 prostate cancer cell migration. Idi siRNA also block this TGFE33 mediated
effects on cell motility (see appendix Figure 40).
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Next, we studied the roles of Idi and 1d3 in TGFI3 effects on migration of DU145 and
PC3 cells. DU145 as previously shown, were unresponsive to TGFI3 stimulation but responded
to EGF stimulation (see appendix Figure 41). Knock down of Idi or 1d3 had no effect on this
EGF induced migration. TGFI31, EGF (see appendix Figure 42), and TGFf33 (see appendix
Figure 43) induced a significant increase in migration of PC3 cells. Incubation with Idi or 1d3
siRNA completely abolished TGFI3 induced migration. In contrast, these siRNA had no effect
on EGF induced migration in PC3 cells as well.
Migration and motility markers were also observed in PC3 prostate cancer cells upon
TGFf3 1 stimulation. PC3 prostate cancer cells were treated with exogenous TGFf3 1 (5ng/ml) for
lh and 24h, protein extracted, and protein levels analyzed by western blotting. At 24h, Idi and
1d3 protein levels are induced, as previously shown, as were PAl-i and fibronectin levels, both
motility markers (see appendix Figure 44).
We next assessed the effects of TGFI3 1 on matrix metalloproteinases (MMPs). Studies
have shown that TGFf3 acts as a tumor promoter, in induces MMPs in order to degrade the ECM
and increase cell motility. TGFJ3 1 induced MMP 1, MMP9, and MMP 13 (see appendix Figure
45) in PC3 prostate cells. Loss of Idi inhibited MMP1 and MMP13 mRNA expression levels
(see appendix Figure 46). Loss of 1d3 inhibited MMP 13 mRNA expression levels, but had no
effect on MMP1 mRNA levels (see appendix Figure 47). This suggests that Idi and 1d3 may
regulate specific MMPs in order to degrade the ECM and increase cell motility.
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4.7 The regulation of TGF/3 late response
We have shown previously that TGFf3 1 is able to down regulate proliferation promoters
while inducing proliferating inhibitors at the late time point, 24h. To observe if these effects on
the levels of Idl or 1d3 were mediated by TGFI3 signaling, inhibitors of TGFI3 signaling
components were used, prior to TGFf3 stimulation. The inhibitors included Receptor I Inhibitor
(SB43 1542), Smad3 Inhibitor (SIS3), and Pl3kinase inhibitor (LY294002). Since Receptor I
inhibitor is capable of blocking TGFI3 1 initial induction of Ids, we then assessed whether late
response is regulated by this receptor. At the 24h time point, Id 1 protein levels were down
regulated, while 1d3 levels were induced in DU1 45 cells. Receptor I inhibitor (SB43 1542),
blocked TGF~ late down regulation of Idi and also blocked both the induction of 1d3 in the
DU145 prostate cancer cell line (see appendix Figure 48). This suggests that both early and late
time point TGFj31 effects on Idl and 1d3 are regulated by TGFf3RI.
We have also shown that loss of Idi is involved in TGFf3 mediated effects on
proliferation in DU 145 prostate cancer cells. However, PC3 prostate cancer cells were
unresponsive, and Idi levels remained stably induced. Studies indicated that upon TGFf3
stimulation in PC3 cells, phosphorylation of AKT, a downstream target of P13 kinase, is induced
and correlates with increased invasive potential 120 To assess if these TGFJ3 effects on Idi
expression is PC3 cells involve the Pl3kinase pathway, Pl3kinase inhibitor (LY294002) was
used prior to TGFfI1 treatment for 24h (see appendix Figure 49). P13K inhibitor (LY294002)
abrogated TGFf31 induction of Idi in the PC3 cell line. Pl3kinase inhibitor was then used to
determine TGFJ3 1 effects on proliferation in prostate cancer line PC3. As previously shown,
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TGFJ3 1 alone, did not have an effect on proliferation. However, Pl3kinase inhibitor (LY) alone
inhibited proliferation of PC3 cells (see appendix Figure 50). This suggests that Idi loss through




The present study compared the relative contributions of Idi and 1d3 in mediate the
effects of TGFf3 on proliferation and migration in cell lines derived from normal prostate
epithelial and prostate cancer cells. Our results show that while down-regulation of Idl is
required for the inhibitory effects of TGF~3 on proliferation of prostate cells, TGFf3 effects on 1d3
protein do not correlate with its inhibitory effects on cell cycle. Although 1d3 did not play a role
in TGFf3 effects on proliferation, it was shown to play a role in TGFf3 effects on migration.
5.1 Basal expression
Previous studies have indicated that TGFI3 1 levels are elevated in patients with metastatic
carcinoma125. We have shown that mRNA and protein TGFI3 ligands and its respective receptors
are indeed expressed in prostate cancer cell lines except in LNCaP cells. This correlated with
previous published studies and similar results were found on protein levels of TGFI3 ligands and
receptors 120
This study provides a detailed analysis of Idi and 1d3 expression and their involvement in
TGFf3 effects on proliferation and migration in prostate cell lines. Prior studies indicate that Idi
and 1d3 protein levels are higher in several prostate cancer cell lines89’ 103 Increased Idl
expression has been correlated with enhanced malignant potential of breast, prostate, and ovarian
tumors103’ 126 Idi and 1d3 expressions have also been proposed to play a role in sustained
40
41
proliferation of the malignant triple negative (TN) breast cancer cells127 We show that Idi and
1d3 basal expression was increased in prostate cancer cell lines.
5.2 TGF/Jleffects on Idproteins
We have shown that TGFf31 is able to increase Idi and an 1d3 mRNA and protein levels.
TGFI3 1 stimulation was shown to dramatically decrease Id levels in in breast cancer cell lines,
which we confirmed in our studies’28. Literature has also shown that the early induction of Idi is
mediated by Smad3 in normal epithelial cells’29. TGFj3 effects on Idi and 1d3 protein levels are
mediated by Smad3 mediated. In contrast, inhibitors against non- Smad pathways including P13
kinase and MAP kinase had no effect on early induction of Idi or 1d3 protein levels in DU145
prostate cancer cell line by TGFf31. This suggests DU145 cell line as a model to represent the
early stage of tumor progression where regulation is Smad dependent.
5.3 TGF/i1- Idi cross- talk in cell proI~feration
In normal epithelial cells, TGFJ3 causes cell cycle arrest in the Gi phase in order to
inhibit cell proliferation64; however, many epithelial cancers develop resistance to growth
inhibitory effects of TGFf3 in later stages of the disease. Indeed, TGFf3 acts as a tumor promoter
in these diseased cells through its positive effects on migration, invasion, angiogenesis and
metastasis130. The data presented in this study showed that TGFf31 exerted differential effects on
proliferation in different cell lines derived from normal prostate epithelial and cancer cells. TGFI3
inhibited proliferation in PZ-HPV7 and DU145 cells while it had no effect on proliferation of
LNCaP and PC3 cells. These results confirmed previous findings on the effects of TGFJ3 on
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proliferation of different prostate cell lines 131, 132 showing similar inhibitory effects of TGFI3 on
proliferation of DU145 cells and lack of this inhibition in LNCaP and PC3 cells. These results
indicate that, like early stage tumor cells, DU 145 cells retain their ability to respond to TGFI3
effects on proliferation. The inability of TGFf3 to affect proliferation in LNCaP cells is consistent
with the lack of TGFf3RII expression’33. PC3 cells contain TG93 receptors and exogenous TGFf3
induces phosphorylation of Smad3 in these cells, indicating the presence of TGFf3 signaling
components; however, TGFJ3 does not exert any inhibitory effects on proliferation of PC3 cells.
These results indicate that PC3 cells represent a cell line model of late stage prostate cancer cells
which have developed a resistance to growth inhibitory effects of TGFI3 but retains TGFf3
signaling involved in its pro-tumorigenic effects.
Idi knockdown inhibited proliferation in both DU145 and PC3 prostate cancer cells
correlating with previous literature on prostate cancer studies89. Our data on TGFI3 1 effects on
Idl and the inhibition of proliferation after Idi knockdown confirms a role of Idi in cell
proliferation. Interestingly, knockdown of 1d3 also resulted in reduced proliferation of DU145
and PC3 cells. This indicates that, as previously shown, 1d3 also plays a role in cell
proliferation89. However, TGFf3 treatment increased expression of 1d3 in both DU145 and PC3
cells, suggesting its inhibitory effects on proliferation do not involve 1d3. Immunohistochemical
staining for Ki-67, a marker for proliferation, in prostate cancer tumors showed a correlation
between a significant increase of Ki-67protein and Gleason score134. In our studies, using
DU145 prostate cell line, we assessed the protein levels of Ki-67. The results showed during the
same time period that Idi protein levels were down regulated; Ki-67 protein levels were also
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decreased. One study using prostate cancer cells has also showed that the ratios of Ki-67 and
PCNA expression levels in LNCaP and PC3 cells were higher, in prostate cancer tissue
samples135. We show here that in DU 145 prostate cancer cell show that, PCNA protein levels
were decreased after prolonged exposure to TGFI3 1. However, 1d3 protein levels remain stably
induced at all time points studied. We also showed that loss of Idi has an additive effect on the
reduction of Ki-67 protein levels by TGFf3 1. This further shows the correlation of Idi, but not
1d3 in TGFf3 1 mediated effects on cell proliferation.
TGFf3 effects on proliferation have been shown to involve p21 and p27 inhibitors of
cyclin-dependent kinases” 133 In the present study, TGFf3 induced the expression of p21 in PZ
HPV7 and DU 145 cells which correlated with its inhibitory effects on cell proliferation and Idi
protein levels. We also showed that knock down of Idi alone is able to up regulate p21 protein
levels in DU145, but not in PC3 cells. This was interesting because we have also observed that
loss of Idi in both cell lines inhibits proliferation. This suggests that while Idl mediates TGFI31
effects on proliferation through the induction of p21 in DU145 cells, knock down of Idi alone is
still able to inhibit proliferation in p21- null PC3 cells. This confirmed our previous studies that
loss of Idi or 1d3 is able to inhibit proliferation in p21-null PC3 cells103. Some studies have also
suggested that TGFj3 also induces p27 expression in epithelial cells’23’ 136 However, we did not
observe any changes in p27 protein levels upon TGFf3 1 treatment in prostate cells indicating that
TGF~3 effects on proliferation in these cells may not involve p27.
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5.4 TGF/J1- Id cross- talk in Cell Migration
Literature has shown that TGFf3 exerts biological effects on migration and angiogenesis
in PC3 cells’37’ 138 Understanding the intracellular mechanistic switch involved in altering TGFI3
effects from growth inhibitory to pro-tumorigenic is very important and DU145 and PC3 prostate
cancer cell lines provide interesting model systems for such studies.
Previous studies, including our own, have shown that TGFf3 is able to promote migration
and invasion in PC3 cells 120 Interestingly, TGFf3 up regulated Idi and 1d3 protein in these cells
and knockdown of either Idi or 1d3 abolished TGFI3 effects on cell migration. This correlates
with previous studies which indicated that Idl/1d3 double-knockdown decreased the ability of
pancreatic cells to migrate’9. These results indicate that in late stages of the disease, tumorigenic
effects of TGFf3 require up regulation of both Idi and 1d3. However, neither Idi nor 1d3
knockdown had any effects on the migratory abilities of PC3 cells in response to EGF,
suggesting that EGF effects are mediated by signaling pathways which do not involve Idi or 1d3
proteins. We have shown that TGF 133 is also able to induce migratory and invasive capabilities
of PC3 cells. The present study has shown that TGFI31 and TGF133 exert similar effects on Idi
and 1d3 expression in prostate cancer cell lines DU145 and PC3. Knock down of Idi or 1d3 also
abrogated TGFJ33 effects on promotion of migration and invasion.
Studies have also shown that these TGF13 effects on cell migration involve the
phosphorylation of Smad3 and AKT. Specific inhibitors of P13 kinase and Smad3 blocked
TGFf3 induced migration in PC3 cells 120 AKT is able to enhance complex formation of bHLH
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transcription factors and co-activator p300’39. This suggests possible links to Smad and non
Smad pathways in which Idl or 1d3 mediate proliferation or migration in PC3 cells.
During invasion, the extracellular matrix (ECM) is remolded through the production of
MMPs. TGFI3 1 is able to stimulate the increase of PAl-i and induce fibronectin secretion in
order to alter the formation of ECM 87 140 These proteins play a role in cell adhesion and
invasion. We show here that TGFI31 is able to induce the protein levels of PAl-i and
fibronectin. TGFJ3 also induced the expression of MMP-1, MMP9, and MMP-13 in PC3 cells.
Literature has shown that all three of these MMPs have shown increased expression in primary
tumors 141, 142 We show that loss of Idl or 1d3 plays a role in the regulation of MMP mRNA
expression, thus demonstrating a role of Ids in TGF~ regulation of MMPs in PC3 cells.
5.5 TGF/i1 mediated effects on Ids at late time points
We have shown that early effects by TGFI31 on Idi or 1d3 involve TGFf3RI and Smad3,
but wanted to know the regulation of Id 1 or 1d3 at the later time point. Previous studies have
shown P13- kinase regulates Idi effects on keratinocyte cell survival 143 Over expression of Idi
has been shown to induce endothelial progenitor cells (EPCs) proliferation, while inhibition of
the P13- kinase pathway blocked Idi effects on EPCs 144, 145 Idi over expression in esophageal
cancer cells (ECC) also causes an increase of metastatic potential and treatment with inhibitors
of P13 kinase pathway attenuated tumor promoting effects of Idi ‘~ Our studies show that P13
kinase inhibitor (LY294002) was able to abrogate TGFf3 1 effects on Id 1 protein levels in
PC3cells, suggesting this pathway as a possible mechanism for the regulation of Idi.
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P13 kinase pathway is activated by TGFf31 and TGFf33 in PC3 cells, but not in DU145
cells. This was demonstrated by increased p-AKT protein levels and increased migration and
invasion upon TGFf3 stimulation; P13 kinase inhibitor was able to abrogate these TGFf3 effects
on phosphorylation of AKT and migration 120 We have also shown that TGFI31 is unable to
inhibit proliferation in PC3 cells, partly due to increased levels of Idi protein expression. We
next used P13 kinase inhibitor (LY294002) to determine its effects on Idi protein levels.
LY294002 blocked TGFJ31 induction of Idi in PC3 cells. Studies have shown that this P13
kinase inhibitor is able to induce the accumulation of cells in the Gi phase in order to inhibit
proliferation of choroidal melanoma cells (0CM-i)’46. We have shown that LY294004 blocked
cell proliferation of PC3 cells. This suggests that TGFf3 effects on Idi may possibly be regulated
by the P13 kinase pathway.
CHAPTER SIX
CONCLUSION
In conclusion, we show a strong correlation between down regulation of Idi and
TGFI3 1- induced inhibition of cell proliferation in DU 145 cells but not in PC3 cells. Failure to
induce down regulation of Idi in PC3 cells was associated with lack of TGFf3 effects on
proliferation. On the other hand, TGFf3 induced expression of Id3 in all cell lines that were
independent of cell proliferation, suggesting that while reduction in Id 1 levels may be pre
requisite for inhibitory effects of TGFf3 on cell proliferation, 1d3 does not appear to play any role
in these effects. We show that in the early stages, TGFI3 down regulates Id 1 in order to induce
p21, thereby inhibiting cell proliferation. We also show that in the later stages, TGFf3 effects on
migration may involve regulation of Idi by P13 kinase pathway (see appendix Figure 51).
This study also showed that both Idi and 1d3 play a role in TGFI3 effects on cell
migration. Although this study provided sufficient data to support the role of Idi and 1d3 in
biological effects of TGFj3, it would be interesting to determine the actual binding partners of
these bHLH transcription factors. It would also be interesting to determine if the Id2 or Id4
isoforms also play a role in TGFf3 mediated effects. These results provide insight on some of the
mechanisms involved in TGF~’s transition from tumor suppressor to tumor promoter. Future
studies to delineate TGFf3 mediated effects in prostate cancer cells are necessary and may
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Figure 1. Illustration showing the location of the prostate and surrounding organs. A normal
human male prostate is about the size of a walnut. The prostate sits above the base of the penis
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Figure 2. Synthesis and secretion of TGFf3 superfamily members. TGFI3 superfamily members
are synthesized in a precursor form. Once secreted, TGFf3 superfamily ligands that remain
associated with the pro-region and other interacting proteins are biologically inactive. A variety





Figure 3. TGFI3 Receptors phosphorylate specific Smads. The TGFf3 Receptor II is able to form
a receptor complex with other type I receptors such as ALK1, ALK2, and ALK5 and able to
activate alternative signaling pathways. The ALK1 or ALK2 receptors are capable of
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Figure 4. The Smad family of signaling mediators. Receptor associated Smads (1,2,3,5,8) are














Figure 5. Illustration of the TGFI3 signaling pathway. Upon phosphorylation by the receptor
complex, Smad 2 and Smad 3 undergo heterodimerization with Smad 4. This Smad dimer then
moves into the nucleus to interact with co-activators, co-repressors, and other transcription








Figure 6. Schematic showing TGFj3 in cancer. In normal epithelial cells, TGFf31 works through
its signaling pathway to stop the cell cycle at the 01 stage in order to inhibit proliferation, induce
differentiation, or promote apoptosis. But, when a cell becomes metastatic, the tumor becomes
more resistant to growth inhibition and these cancer cells continue to proliferate in the presence
of TGFf3. TGFf3 produced by advanced cancer cells then act on surrounding cells causing
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Figure 7. Inhibitor of Differentiation proteins are unable to bind to DNA. Id, inhibitor of
differentiation, proteins are a family of proteins that heterodimerize with basic-helix-loop-helix
(bHLH) transcription factors in order to inhibit DNA binding of bHLH proteins. These proteins
contain the HLH- dimerization domain, but lack the basic DNA binding domain, and thus













HPV7 epithelial cells from histologically normal adult human prostate
RWPE 1 epithelial cells from histologically normal adult human prostate
RWPE2 epithelial cells derived from RWPE 1 cells by transformation
DU 145 prostate carcinoma, derived from the brain of a 69 year olf caucasian male
PC3 prostate adenocarcinoma derived from the bone of a 62 year old caucasian male
LNCaP prostate carcinomna from the supravicular lymph node
55
Table 2. Primers for Ids
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Product
Gene Forward Reverse Size
Id 1 5’ -GTTACTCACGCCTCAAGGAGC-3’ 5’ -AGAAGAAATGAGACCGGCGGG-3’ 55 Obp
1d2 5’ -CTTAGCCAGGTGGAAATCCTA-3’ 5’ -GTCGTTGGAGATGACAAGTTC-3’ 400bp
1d3 5’-CTATTGTCAGCCTGCATCAC-3’ 5’-CAGTGCTTTGCTCTCATTTG-3’ 250bp
1d4 5’-TGCAGTGCGATAGAACGAC-3’ 5’-AGCTGCAGGTCCAGGATGTA-3 600bp
L-19 5’-GAAATCGCCAATGCCAACTC- 3’ 5’-TCTTAGACCTGCGAGCCTCA-3’ 405bp
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Figure 8. Idi and 1d3 mRNA levels in prostate and prostate cancer cell lines. Semi-quantitative
RT-PCR was performed using RNA from PZ-HPV7, RWPE1, RWPE2, DU145, PC3, and
LNCaP cells to determine relative mRNA levels of Idl and 1d3. The mRNA levels in all cell
line samples were normalized against L- 19, which served as an internal control.












Figure 9. Protein levels of Idi and 1d3 proteins in normal prostate epithelial and prostate cancer
cell lines. Western blot analysis was performed to determine relative protein levels Idi and 1d3
in PZ-HPV7, RWPE1, RWPE2, DU145, PC3, and LNCaP cells. Western blots for 13-actin were






Figure 10. mRNA levels of Idi and 1d3 in normal prostate epithelial and prostate cancer cell
lines after six hour serum starvation. Semi-quantitative RT-PCR was performed using RNA
from PZ-HPV7, RWPE1, RWPE2, DU145, PC3, and LNCaP cells to determine relative mRNA
levels of Idl and 1d3. The mRNA levels in all cell line samples were normalized against L-19,





Figure 11. Protein levels of Idi and 1d3 basal expression in normal prostate epithelial and
prostate cancer cell lines after six hour serum starvation. Western blot analysis was performed to
determine relative protein levels Idi and 1d3 in PZ-HPV7, RWPE1, RWPE2, DU145, PC3, and








Figure 12. Geo profiles of Idl and 1d3 isoforms in prostate cancer cell lines (NCBI).
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Figure 13. TGFf31 effects on Idi mRNA in normal prostate epithelial cell line PZ-HPV7, and
prostate cancer cell lines, DU145 and PC3 for early time points. Cells were treated with TGFf31
(5ng/ml) for 1 and 8h. Semi-quantitative RT-PCR was performed using RNA from PZ-HPV7,
DU145, and PC3, cells to determine relative mRNA levels of Idi. The mRNA levels in all cell
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Figure 14. TGFJ31 effects on Idi protein levels in normal prostate epithelial cell line PZ-HPV7,
and prostate cell lines DU145 and PC3. Cells were treated with TGFI31 (5ng/ml) for 1 and 8h.
Western blot analysis was performed to determine relative protein levels Idi in PZ-HPV7,
DU145, and PC3 cells. Western blots for 13-actin were performed as protein loading controls.
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Figure 15. TGFf31 effects on 1d3 mRNA in normal prostate epithelial cell line PZ-HPV7, and
prostate cancer cell lines, DU145 and PC3 for early time points. Cells were treated with TGFf31
(5ng/ml) for 1 and 8h. Semi-quantitative RT-PCR was performed using RNA from PZ-HPV7,
DU145, and PC3, cells to determine relative mRNA levels of 1d3. The mRNA levels in all cell




Figure 16. Protein levels of TGFf31 effects on 1d3 in normal prostate epithelial cell line PZ
HPV7, DU145, and PC3. Cells were treated with TGFf31 (5ng/ml) for 1 and 8h. Western blot
analysis was performed to determine relative protein levels 1d3 in PZ-HPV7, DU145, and PC3











Figure 17. TGFf3 1 effects on Idl and 1d3 mRNA levels in androgen sensitive prostate cancer cell
line LNCaP. Cells were treated with TGFf31 (5ng/ml) for 1 and 8h. Semi-quantitative RT-PCR
was performed using RNA from LNCaP, cells to determine relative mRNA levels of Idl and 1d3.
The mRNA levels in all cell line samples were normalized against L-19, which served as an
internal control.
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Figure 18. TGFf31 effects on Idi and 1d3 mRNA levels in normal epithelial cell line PZ-HPV7,
and prostate cancer cell lines DU145 and PC3. Cells were treated with TGFJ31 (5ng/ml) for 1
and 24h. Semi-quantitative RT-PCR was performed using RNA from PZ-HPV7, DU145, and
PC3, cells to determine relative mRNA levels of Idl and 1d3. The mRNA levels in all cell line
samples were normalized against L- 19, which served as an internal control
PZ-HPV7 DU145 PC3






0 1 24 0 1 24 0 1 24 h
Q
0
Figure 19. The effects of TGFf3 1 on Idi and 1d3 protein levels and fold change in normal
epithelial prostate cell line, PZ-HPV7, and prostate cell lines, DU145 and PC3. Cells were
treated with TGFf31 (5ng/ml) for 1 and 24h. Western blot analysis was performed to determine
relative protein levels 1d3 in PZ-HPV7, DU145, and PC3 cells. Western blots for J3-actin were



















Figure 20. TGFf32 and f33 effects on Id mRNA levels. Cells were treated with TGFf31 (5ng/ml)
for 1 and 8h. Semi-quantitative RT-PCR was performed using RNA from DU145 cells to
determine relative mRNA levels of TGFf32 and TGFJ33. The mRNA levels in all cell line
samples were normalized against L- 19, which served as an internal control
1d4
= L19







Figure 21. TGFf33 (5ng/ml) effects on Idi and 1d3 protein levels in prostate cancer cell lines
DU145 and PC3. Cells were treated against specific siRNA and cells were collected 48h later
after transfection. Western blot analysis was performed to determine relative protein levels Idl
and 1d3 in DU145 and PC3 cells. Western blots for J3-actin were performed as protein loading
controls.
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Figure 22. Dose dependent effects of TGFI3 Effects of different doses of TGFf3 on Idi and 1d3
levels in DU145 cells after treatment with TGFI31 for lhr. Western blot analysis was performed
to determine relative protein levels Id 1 and 1d3 in DU 145 cells. Western blots for f3-actin were
performed as protein loading controls. Each bar represents Mean ± SEM from three independent
experiments. *significantly different when compared with controls (P< 0.05).
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Figure 23. Effects of TGFI3(5 ng/ml) on Idl and 1d3 levels in DU145 cells in the presence or
absence of inhibitors of TGFf3RI (SB43 1542; 5j.tM). ) Effects of TGFj3 (5 ng/ml) on Idi and 1d3
levels in DU 145 cells in the presence or absence of inhibitors of TGFI3RI (SB43 1542; Western
blot analysis was performed to determine relative protein levels Id 1 and 1d3 in DU 145 cells.
Western blots for 13-actin were performed as protein loading controls. Each bar represents Mean
± SEM from three independent experiments. *significantly different when compared with
controls (P< 0.05).
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Figure 24. TGFf3 effects on Smad3 phosphorylation in PZ-HPV7, DU145, PC3, LNCaP and
HeLa cells. Cells were treated with TGFI31 (5ng/ml) for 10, 20, and 30 mins. Western blot
analysis was performed to determine relative protein levels 1d3 in PZ-HPV7, DU145,
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Figure 25. Effects of TGFI3 (5 ng/ml) on Idl and 1d3 levels in DU145 cells in the presence or
absence of inhibitors of Smad3 (SIS3; 31.iM). Effects of TGFf3 (5 ng/ml) on Idl and 1d3 levels in
DU145 cells in the presence or absence of inhibitors of TGFI3RI (SB43 1542; 5~.tM) or Smad3
(SIS3; 3 ~iM Western blot analysis was performed to determine relative protein levels Id 1 and 1d3
in DU 145 cells. Western blots for f3-actin were performed as protein loading controls. Each bar
represents Mean ± SEM from three independent experiments. *significantly different when










Figure 26. Effects of TGFf3 (5 ng/ml) on Idi and 1d3 levels in DU145 cells in the presence or















Figure 27. TGFJ31 effects on proliferation in PZ-HPV7, DU145, PC3, and LNCaP cell lines.
Cell lines were treated with 1 and lOnglml TGFj31 for 48h and analyzed by MTT. Each bar
represents Mean ± SD from a representative experiment. * Significantly different from
















Figure 28. TGFf3 1 effects on DNA synthesis in normal epithelial prostate cell line RWPE1. Cell
lines were treated with 1 and lOng/mi TGFj3 1 for 48h and analyzed by thymidine incorporation.
Each bar represents Mean ± SD from a representative experiment. * Significantly different from
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Figure 29. Comparative effects of TGFf31 on levels of p21, p27, Idi and 1d3 proteins in PZ
HPV7, DU145 and PC3 cells. Cells were treated with TGFj31 (5ng/ml) for 1 and 24h. Western
blot analysis was performed to determine relative protein levels 1d3 in PZ-HPV7, DU145, and










Figure 30. TGFf31 effects on proliferating markers PCNA and K167 protein levels in prostate
cancer cell line DU145. Cells were treated with TGFI31 (5ng/ml) for 1 and 24h. Western blot
analysis was performed to determine relative protein levels Idi, 1d3, PCNA, myc and Ki67 in




Figure 31. Representative images of DU145 and PC3 cells after migration of cells through
transwell. Cells were visualized under lox objectives. EGF (3ng/ml) used as a positive control,
induced migration in both cell lines. Each bar represents Mean ± SEM (n=3). * Significantly











Figure 32. Levels of Idi protein in DU145 and PC3 cells after transfection with control (Contol
A), Idi (Idi siRNA), or 1d3 (1d3 siRNA) specific siRNAs. Cells were treated against specific
siRNA and cells were collected 48h later after transfection. Western blot analysis was
performed to determine relative protein levels Idi and 1d3 in DU145 and PC3 cells. Western





















Figure 33. Loss of Idi or 1d3 protein decreases proliferation rate in PC3 cells. PC3 cells were
treated with specific siRNA for 72h and counted using cellometer.







Figure 34. TGFI31 effects on proliferation ± Idi siRNA in normal epithelial cell line PZ-HPV7.
Cells were treated against specific siRNA and 48h later, treated with TGFf3 1 (5ng/ml) for 48h
and analyzed by MTT.
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Figure 35. Effects of Idi knock down on proliferation of DU145 and PC3 cells in the presence
or absence of TGFj31 (5ng/ml) as determined by MTT assay. Each bar represents Mean ± SD
from a representative experiment. Different letters on each bar represent significant differences



















Table 3. FACs analysis of the effects of Idi
Treament
Gi (%) S (%) G2-M (%)
Control
- 61.2 16.6 22.2
TGFI3 65.6 13.6 20.8
Control siRNA
- 58.9 18.7 22.4
TGFf3 65.6 1 1.3 23.1
Idl siRNA
- 63.9 11.5 24.6
TGFj3 70.3 5.9 23.8
1d3 siRNA
- 66.5 5.3 28.2
TGFJ3 70.2 5.1 24.7
Table 3. FACs analysis of TGFI31 treatment ± Idi or 1d3 in prostate cancer cell line DU145.
Cells were treated against specific siRNA and 48h later, treated with TGF f31 (5ng/ml) for 1 8h,
collected, and analyzed by FACs analysis.
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Figure 36. Knock down of Idi induces p21 in prostate cancer cell line DU145, but not in
PC3 cells. Cells were treated against specific siRNA and cells were collected 48h later after
transfection. Western blot analysis was performed to determine relative protein levels p21 in







Figure 37. Knock down of Idi has an additive effect on TGF~31 downregulation of Ki-67 in
DU145 cells. Cells were treated against specific siRNA and cells were collected 48h later after
transfection. Western blot analysis was performed to determine relative protein levels of Ki-67
in DU145 cells. Western blots for f3-actin were performed as protein loading controls.
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Figure 38. DU145 scratch wound assay ±TGFf31 treatment ±Idl or 1d3 siRNA. Scratch wound
assays were performed following treatment with TGFI3 isoforms for 48h in the presence or
absence of specific inhibitors. Representative images of DU145 cells after migration of cells
through transwell. Cells were visualized under i OX objectives.
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Figure 39. PC3 scratch wound assay ±TGFI31 treatment ±Idl or 1d3 siRNA. Scratch wound
assays were performed following treatment with TGFI3 isoforms for 48h in the presence or
absence of specific inhibitors. Representative images of PC3 cells after migration of cells
through transwell. Cells were visualized under lox objectives.
90
TG933 control siRNA
Figure 40. PC3 scratch wound assay ±TGFf33 treatment ±Idl siRNA. Scratch wound assays
were performed following treatment with TGFf3 isoforms for 48h in the presence or absence of
specific inhibitors. Representative images of PC3 cells after migration of cells through
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Figure 41. Effects of Knockdown of endogenous Idl or 1d3 on TGFf3 effects on cell migration in
prostate cancer cell line DU 145. Representative images of DU 145 cells after migration of cells
through transwell. Cells were visualized under i OX objectives. EGF (3ng/ml) used as a positive
control, induced migration in both cell lines. Each bar represents Mean ± SEM (n=3). *




Figure 42. Effects of Knockdown of endogenous Idi or 1d3 on TGFI3 effects on cell migration in
prostate cancer cell line PC3. Representative images of DU 145 and PC3 cells after migration of
cells through transwell. Cells were visualized under i OX objectives. EGF (3ng/ml) used as a
positive control, induced migration in both cell lines. Each bar represents Mean ± SEM (n=3). *
Significantly different (P < 0.05) compared to untreated controls.
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Figure 43. Idi or 1d3 block TGFI31 or 133
compared to untreated controls.
migration. Each bar represents Fold Change as
94
Figure 44. TGFf31 induces fibronectin and PAT-i. Western blot analysis was performed to
determine relative protein levels Id,1 1d3, fibronectin, and PAl- 1 in DU145 and PC3 cells.











Figure 45. TGFf31 induces MMPs in prostate cancer cell line PC3. Cells were treated for lh and
24h with TGFI31 (5ngIml). Semi-quantitative RT-PCR was performed using RNA PC3 cells to
determine relative mRNA levels of Idl, 1d3, MMP1, MMP9, and MMP13. The mRNA levels in









Figure 46. Loss of Idi effects on MMPs. Idi and 1d3 were knocked down in PC3 cells by
siRNA. Semi-quantitative RT-PCR was performed using RNA from PC3, cells to determine
relative mRNA levels of Idi, 1d3, MMP1, MMP9, and MMP13. The mRNA levels in all cell
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Figure 47. Loss of Idi 1d3 effects on MMPs. Idi and 1d3 were knocked down in PC3 cells by
siRNA. Semi-quantitative RT-PCR was performed using RNA from PC3, cells to determine
relative mRNA levels of Idi, 1d3, MMP1, MMP9, and MMP13. The mRNA levels in all cell













Figure 48. Effects of TGFf31 (5 ng/ml) on Idi and 1d3 levels in DU145 cells in the presence or
absence of inhibitors of TGFf3RI (SB43 1542; 5jiM). Western blot analysis was performed to
determine relative protein levels Idland 1d3 in DU145 and PC3 cells. Western blots for j3-actin
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Figure 49. Effects of TGFj3 (5 ng/ml) on Idi and 1d3 levels in PC3 cells in the presence or
absence of inhibitors of Smad3 (SIS3) or P13K (LY294002). Western blot analysis was
performed to determine relative protein levels Id 1 and 1d3 in DU 145 and PC3 cells. Western











Figure 50. Inhibitor against P13K (LY294002) inhibits proliferation effects in prostate cancer
cell line PC3. Cells were treated against P13K (LY294002) and 48h later, treated with TGFI31
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Figure 51. TGFI3 1 effects on proliferation and migration are regulated by Id 1 and 1d3 proteins.
In early stages of tumor progression, TGFI3 1 inhibits Id 1 protein levels which in turn induce p21,
thereby, inhibiting cell proliferation inDU 145 cells; In the later stages, TGFf3 1 induces Id 1 and
1d3 protein possibly through regulation of P13 kinase pathway in order to promote cell migration
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